Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

On September 2, 2021 Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, reported members of the executive team will participate in the following upcoming virtual investor conferences (Press release, Kezar Life Sciences, SEP 2, 2021, View Source [SID1234587190]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Virtual Healthcare Conference
Thursday, September 9, 2021, 4:00 PM ET
Presenter: John Fowler, Chief Executive Officer, and Noreen Roth Henig, M.D., Chief Medical Officer

H. C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13, 2021, 7:00 AM ET
Presenter: John Fowler, Chief Executive Officer

A webcast of both presentations may be accessed at the "Events & Presentations" section of Kezar’s website at View Source Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conferences.

Autolus Therapeutics to participate in upcoming virtual investor conferences

On September 2, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will participate in three upcoming virtual investor conferences (Press release, Autolus, SEP 2, 2021, View Source [SID1234587189]). An audio webcast of any presentations will be available live. You can access the webcasts via the Events section of the Autolus website. An archived version will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AC Immune to Participate in Upcoming virtual Investor Conferences in September

On September 2, 2021 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that company management will participate in the following upcoming virtual investor conferences (Press release, AC Immune, SEP 2, 2021, View Source [SID1234587188]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference
One-on-one meetings – Wednesday, September 8, 2021

Morgan Stanley’s 19th Annual Global Healthcare Conference
One-on-one meetings – Friday, September 10, 2021

H.C. Wainwright 23rd Annual Global Investment Conference
Corporate presentation – On-demand starting on September 13, 2021
One-on-one meetings – Wednesday, September 15, 2021

During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company’s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as well as the recent top-line data from Lauriet Phase 2 trial evaluating semorinemab in mild-to-moderate AD.

A webcast of the corporate presentation will be available on the Events Page of AC Immune’s website.

Turning Point Therapeutics to Participate In Upcoming Investor Conferences

On September 2, 2021 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23rd Annual Global Investment Conference on Sept. 13 (Press release, Turning Point Therapeutics, SEP 2, 2021, View Source [SID1234587185]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis is scheduled to present a company overview and participate in a question-and-answer session at 2:00 p.m. ET on Sept. 9 and present a company overview at 7:00 a.m. ET on Sept. 13. Both sessions will be accessible via webcast through the Investors page of www.tptherapeutics.com.

Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference

On September 2, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, "Autologous, Allogeneic CAR-T, CAR-NK & More – Exploring the State of Play in Cell Therapy," at the Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9, 2021 at 7:40 a.m. PDT/10:40 a.m. EDT (Press release, Atara Biotherapeutics, SEP 2, 2021, View Source [SID1234587181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the panel will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the live presentation.